A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
Breelyn A. Wilky(Johns Hopkins University), Nilofer S. Azad(Bloomberg (United States))
Cited by 37
Related Papers
Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial
|Nature Communications|2024|35